阿斯利康：这家强大的制药公司在第三季度财报前被低估 (NYSE:AZN)
· seekingalpha.com
尽管近期遭遇挫折，但凭借强劲的产品线和研发管线的实力，阿斯利康仍然是长期买入的选择。点击此处阅读更多关于AZN的内容。
If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and ...